Gilead Sciences, US Government Settle Patent Case Over HIV Prevention Drugs
(Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention ...
GoodRx Holdings: Strong Business Fundamentals and Undervalued Potential Justify Buy Rating ...
Leerink Partners analyst Michael Cherny has maintained their bullish stance on GDRX stock, giving a Buy rating on January 10.Stay Ahead of the ...
Irish Mirror on MSN21 小时
Nurse with HIV and her dad speak out as new HSE awareness campaign says sex is possible ...
Aoife, a nurse, first went public with her HIV diagnosis in 2023 to tackle stigma and discrimination. She said that she was ...
BizPac Review8 小时
NIH is used your taxes in 2023 to study transgender women in Thailand, RandoLand.us reports
The American government truly has wasting taxpayer dollars down to a science, but some of the ways they’ve decided to blow your hard-earned money are shocking. X […] ...
Chicago Inspector General finds Fire Department covered for supervisor asleep at wheel
Fox News correspondent Matt Finn joins 'Special Report' with the latest on lawsuits over the Eaton fire and arrests for ...
DC hotels booked for inauguration
Princess Kate Middleton opened up about the side effects of chemo when she visited the Royal Marsden Hospital in London, ...
The potentially lethal sexually transmitted infection (STI) syphillis is on the rise ...
Newly-released health data shows a huge rise in cases of syphillis in the North East between 2022 and 2023. The region saw a ...
Merck & Company: Strategic Shifts and Upcoming Catalysts Amidst Keytruda Challenges
Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...